Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain drugs
Biotech
Latigo laces up for $247M IPO to fund rival to Vertex’s Journavx
Latigo has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
James Waldron
Aug 4, 2026 7:55am
Latigo preps IPO to fund non-opioid rival to Vertex’s Journavx
Jul 19, 2026 2:07pm
Lilly buys 4E to beef up its non-opioid pain pipeline
Jun 16, 2026 2:34pm
Lilly shakes up pain pipeline as part of quarterly R&D clearout
Aug 7, 2025 8:28am
Vertex drops asset in acute pain after phase 2 fail
Aug 4, 2025 5:34pm
Latigo saddles up with $150M to advance non-opioid pain assets
Mar 17, 2025 5:00am
